Clinical trials: Intravenous Administration
Epilepsy, Partial Onset Seizures
An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures
To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.
- Trial name
- NCT01407523
- Testing
- Levetiracetam
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- UCB Japan Co. Ltd.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary assessment of the anti-leukemia activity of…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
- Trial name
- NCT01684150
- Testing
- EPZ-5676
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Epizyme, Inc.
Healthy Volunteer
A Study of TAK-951 in Healthy Adults
It is hoped that a medicine called TAK-951 will eventually be used to treat nausea and vomiting. Before then, the sponsor needs to understand how the body processes TAK-951 in healthy adults.
- Trial name
- NCT04486950
- Testing
- TAK-951
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Takeda
Aspergillosis, Candidemia
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
The purpose of this study is to provide anidulafungin and voriconazole to healthy subjects to determine the drug concentration in the lung.
- Trial name
- NCT00940017
- Testing
- anidulafungin and voriconazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heart Failure
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart…
- Trial name
- NCT01300013
- Testing
- Omecamtiv mecarbil
- Where
- 150 sites in United States, Australia and 17 more
- Volunteers
- 614 people
- Sponsor
- Cytokinetics
Skeletal Muscle Relaxation
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects
This is a single-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS3797 in Chinese adults.
- Trial name
- NCT05701826
- Testing
- HRS3797
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Healthy Volunteers, Anti-Bacterial Agents
A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers
To evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of N-Rephasin® SAL200 following single and multiple ascending doses in healthy male volunteers after continuous intravenous infusion over 60 minutes.
- Conditions
- Healthy Volunteers, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus Aureus, Methicillin-Sensitive Staphylococcus Aureus Infection
- Trial name
- NCT03446053
- Testing
- N-Rephasin® SAL200
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Intron Biotechnology, Inc.
Healthy
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
The main objective of Part A is to investigate basic pharmacokinetics of BI 685509 and total radioactivity, including mass balance, excretion pathways and metabolism following administration of BI 685509 to healthy male subjects.
- Trial name
- NCT05515328
- Testing
- [¹⁴C] BI 685509 formulation 1, [¹⁴C] BI 685509 formulation 2, BI 685509 formulation 3
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Crohn's Disease (CD)
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab.
- Trial name
- SEQUENCE (NCT04524611)
- Testing
- Risankizumab, Ustekinumab
- Where
- 300 sites in United States, Argentina and 29 more
- Volunteers
- 527 people
- Sponsor
- AbbVie
Patients With Candidemia and/or Invasive Candidiasis
A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS9432 in patients with candidemia and/or invasive candidiasis
- Trial name
- NCT06194201
- Testing
- HRS9432, Caspofungin Acetate for Injection
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Healthy
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of PF-06730512 in healthy subjects.
- Trial name
- NCT03146065
- Testing
- PF-06730512
- Where
- Belgium
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants
Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion of XTMAB-16 (formerly referred to as KBMAB-16) in normal healthy male and female participants.
- Trial name
- NCT04971395
- Testing
- XTMAB-16 2 mg/kg, XTMAB-16 4mg/kg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Xentria, Inc.
Immune Thrombocytopenic Purpura
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
This trial is designed as a multi-centre, single-dose, exploratory dose-finding, open label trial evaluating the safety and efficacy of Sym001 in 4-9 consecutive cohorts. Subjects will receive a single IV dose of Sym001.
- Trial name
- NCT00718692
- Testing
- Sym001
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 61 people
- Sponsor
- Symphogen A/S
Influenza
A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza
This open-label study will assess the pharmacokinetics/pharmacodynamics and safety of intravenous (iv) Tamiflu (oseltamivir) in 3 cohorts of children, aged 6-12, 3-5 and 1-2 years, with influenza infection.
- Trial name
- NCT01033734
- Testing
- oseltamivir [Tamiflu]
- Where
- 38 sites in United States, Israel and 1 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Healthy
PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.
The hypothesis of this trial is that the test drug (Eritromax ®) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ®) in healthy subjects following administration of single intravenous…
- Trial name
- NCT01685333
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Prostate Cancer
AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of…
- Trial name
- NCT00519233
- Testing
- AGS-1C4D4
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Astellas Pharma Inc
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
The purpose of this study is to determine whether TZP-101 is effective in the treatment of symptomatic gastroparesis due to diabetes.
- Trial name
- NCT00612014
- Testing
- 5% dextrose in water, TZP-101
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 78 people
- Sponsor
- Tranzyme, Inc.
Leukaemia
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
Primary Objective: Dose escalation: To determine the maximum tolerated dose (MTD) of SAR440234 administered as a single agent in participants with relapsed or refractory acute myeloid leukemia (R/R AML), high risk myelodysplastic…
- Trial name
- NCT03594955
- Testing
- SAR440234
- Where
- 4 sites in United States, France
- Volunteers
- 7 people
- Sponsor
- Sanofi
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)
Multicenter, randomized, open-label, paralled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in…
- Trial name
- NCT01662687
- Testing
- Sancuso patch, Kytril inj.+Kytril tab.
- Where
- South Korea
- Volunteers
- 276 people
- Sponsor
- LG Life Sciences
Sleep Apnea
A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery
The main aim is to see if danavorexton can help improve people's breathing in the recovery room after abdominal surgery.
- Trial name
- NCT05814016
- Testing
- Danavorexton
- Where
- 19 sites in United States
- Volunteers
- 41 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.